1. AF and PCI in Practice

3. Program Goals

4. Antithrombotic Therapy for AF and PCI

5. WOEST Trial: Triple vs Dual Therapy

6. WOEST Trial: Omission of Aspirin Reduces Bleeding

7. WOEST Trial: Omission of Aspirin Reduces Thrombosis

8. 2014 ACC/AHA/HRS Guidelines for AF

9. 2014 European Consensus: Antithrombotic Management in AF Patients With ACS/PCI

10. AF + PCI: A North American Perspective -- 2016 Update

11. AF + PCI: A North American Perspective -- 2016 Update (cont)

12. Antithrombotic Therapy for AF and PCI

13. PPI Use Reduces GI Bleeding Risk

14. Bleeding Reduction Strategies

15. Which Antiplatelet Agent to Discontinue?

16. RE-DUAL PCI Study Design

17. RE-DUAL PCI Primary Endpoint: Time to First Bleeding Event

18. RE-DUAL PCI: Rates of TIMI Major Bleeding

19. RE-DUAL PCI: Rate of Intracranial Hemorrhage

20. RE-DUAL PCI: Time to Death or Thromboembolic Event, or Unplanned Revascularization

21. RE-DUAL PCI: Additional Individual Thromboembolic Endpoints

22. PIONEER AF-PCI Study Design

23. PIONEER AF-PCI: Primary Endpoint Results

24. PIONEER-AF PCI: Thrombotic Events

25. PIONEER-AF PCI: Major Adverse Cardiac Events

26. Clinical Practice Implications of Trial Data

27. New ESC Focused Update on DAPT in CAD

28. Summary

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)

32. Abbreviations (cont)